Breadcrumb

[A18-69] Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2018-10-16 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Executive summary of dossier assessment  [PDF, 92 kB] (German version) Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A19-21] Durvalumab (non-small cell lung cancer) - Addendum to Commission A18-69
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2019-01-15 Executive summary of dossier assessment (German version) 92 kBPDFdownload file
2019-01-15 Dossier assessment (German version) 2 MBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Health information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Durvalumab (Imfinzi) for the treatment of advanced lung cancer

Federal Joint Committee (G-BA)

2019-04-04 A G-BA decision was published.

G-BA documents on this decision



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close